Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
- PMID: 15539009
- DOI: 10.1007/s11892-004-0054-0
Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
Abstract
Current treatment of the nephropathy complication of diabetes mellitus is suboptimal in halting the progression of the complex disease. Among the irreversible effects of sustained hyperglycemia is the heightened formation of advanced glycation end products (AGEs). The role of AGEs in diabetic nephropathy has been established by years of basic research. This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
